plasia,12 despite having progestins from the ovary and adrenal gland, In these animals, the exclusive expression of PR-B contributes to, rather than inhibits, endometrial cell proliferation, both in response to progestins alone and to the presence of progestins and estrogen. 14 Recently, a functional polymorphism (+331G/A) in the promoter of the hPR-B gene increased the expression of the hPR-B isoform and its presence was associated with a statisticaily significant, almost two-fold increased risk for endometrial cancer in women participating in the Nurse's Health Study. 15 The increase in endometrial cancer was most evident in overweight women; those with a body weight index >28 kg/m 2 had a 4.71-fold risk of endometrial cancer.
In vitro studies have shown that hPR-B alone may promote cell growth by interacting with the estrogen receptor and stimulating the Src/p21ras/Erk pathway. 16 These observations suggest that PR-A in the endometrium is necessary to oppose estrogen-induced proliferation as weil as PR-B-dependent proliferation. However, there is conflicting data regarding the role ofhPR-B in the pathogenesis and metastasis of endometrial cancer. In one study hPR-B was reported to be the dominantly expressed isoform in metastatic endometrial cancer,17 while in another study the down-regulation of hPR-B was predicted to be associated with poorly differentiated endometrial cancers that would not respond to progestin therapy,18 and an additional report noted that both isoforms were sinlilarly expressed in well-differentiated endometrial cancer. 17 Another report has indicated that moderately differentiated cancers expressed more hPR-B and poorly differentiated cancers expressed more hPR_A. 19 This lack of consistency could be due to many reasons, including technical issues, sampling problems, and differences in histological diagnosis.
Two reports from the Blok Laboratory in this issue of the Journal focus on the two isoforms of the human progesterone receptor and their effects on gene regulation when exposed to progestins. 20 ,21 Smid-Koopman et al. have used the histologically weil-differentiated Ishikawa (type 1, endometrioid) human endometrial cancer cell line to generate sub-cloned cells expressing one or both of the hPR isoforms. 20 These ceils also differ from the parent ceils in that they lack estrogen receptor-u and contain minor amounts of estrogen receptor-ß and androgen receptor. The investigators have used these celilines to study the differential role of the progesterone receptor isoforms in progesterone-regulated growth and gene regulation. Progestin-induced growth inhibition was demonstrated in ceillines containing hPR-A and/or hPR-B, and apoptosis was confirmed in longer term cultures. The investigators then studied progesterone-regulated gene expression among a group of genes they had previously identified to be regulated in progestin receptor-expressing endometrial cancer cell lines. 2o ,22 Using cDNA microarrays, the investigators dem on-strated selective regulation of gene expression by these isoforms: For example, only PR-A regulated the gene expression of integrin-ß4. hPR-B highly regulated the gene for amphiregulin. Insulin-like growth factor binding protein (IGFBP3) was only regulated by ceIls expressing hPR-B and hPR-A/B. PR-AlB highly regulated the gene for metaIlothionine-1L (MT 11 ). The authors concluded that ceIl lines expressing different amounts ofhPR-A and hPR-B displayed a differential gene regulation pattern when exposed to progestins.
Hanekamp et al., having previously reported that hPR-Bpositive ceIl lines express siguificantly higher levels of metastasis-related genes, compared gene expression patterns of endometrial cancer ceIl lines that expressed hPR-A, hPR-B, or hPR-A/B and compared differences in gene and protein expression to difIerences in in vitro invasive capacity.21.23.24 They addressed the possibility that cancers with impaired Ecadherin function are associated with more invasive and metastatic cancers. In hPR-B-expressing ceIl lines the genes for the cell-cell adhesion molecules E-cadherin and P-cadherin were decreased while in the exclusively PR-A-expressing cell lines these genes were expressed at the same or somewhat higher levels than in the wild type Ishikawa endometrial cancer ceIllines. 21 Western blot analysis confirmed E-cadherin to be non-detectable in hPR-B-expressing cell lines. E-cadherin was expressed in hPR-A-expressing lines and its expression was somewhat up-regulated by progestins. Using a modified Boyden chamber assay, hPR-B and hPR-A/B expressing cell lines demonstrated a significantly increased rate of invasion compared with hPR-A expressing celilines (P < .000). Medroxyprogesterone acetate (MP A) effectively inhibited invasion by hPR-B and hPR-A/B expressing ceIllines but had no effect on hPR-A-expressing lines. MPA does not affect expression of cadherins in these cells. 24 Further, using immunohistochemistry the investigators report that as human endometrial cancers became less weil differentiated or were more deeply invasive into the myometrium, expression of E-cadherin was strongly decreased. Others have shown an increase in local recurrence and lymph node metastasis associated with a decreased E-cadherin expression. 12 hPR-A cells that express E-cadherin or P-cadherin when exposed to antibodies to either of these proteins will be stimulated to invade in vitro.
Based on their observations the authors hypothesize that, in hPR-B-expressing cel! lines, ligand-free cytoplasmic hPR-B has a function in a signal pathway that stimulates loss of cell-cell adhesion and fosters invasion. 24 Further, they posit that relocalization of the receptor to the nucleus fol!owing binding ofligand would render the hPR-B unavailable for this function, resulting in decreased invasive metastasis. The authors suggest that a loss ofhPR-A in endometrial cancer may result in over-expression of hPR-B, which contributes to progression to a potentially more metastatic cancer. 24 The establishment of the stable sub-cloned endometrial cancer cell lines reported in the Journal has led to the development of new observations on the molecular biology of endometrial cancer and the role of progesterone receptor iso-Schwartz forms in this disease. This is part of an extraordinary amount of molecular biological information regarding PR isoforms that has accumulated in the last three decades. 6 However, it remains to be seen whether these observations reflect basic principles or the unique characteristics of these highly inbred and selected sub-clones. After all, the parent cells were abnormal cancer cells at the outset. The practical answers may only be found in the clinical outcomes of the applications of principles that come out of work such as the reports published in this Journal. The need for these answers is urgent, as there has been no significant change in the clinical management of primary endometrial cancer beyond lymph node staging at the time of surgery, which was introduced 20 years ago. We also need new tools to exploit these observations. Using commer-ciaIly available immunohistochemical stains in our clinical laboratories, we still cannot reliably recognize PR_B?S At a time when so few advanced and recurrent endometrial cancers respond to hormonal and cytotoxic chemotherapy and the ratio of estimated deaths to new cases continues to slowly increase in the United States from 0.12 in 1990 to 0.18 in 2005, much more laboratory and translation al research needs to be done in this disease, the fourth most common site for cancer in American women. 1 • 2
